Additional file 1: of Public health and chronic low chlordecone exposures in Guadeloupe; Part 2: Health impacts, and benefits of prevention Vincent Nedellec Ari Rabl William Dab 10.6084/m9.figshare.c.3622139_D1.v1 https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Public_health_and_chronic_low_chlordecone_exposures_in_Guadeloupe_Part_2_Health_impacts_and_benefits_of_prevention/4397012 Table A: Annual impacts and costs of liver cancer in Men exposed to chlordecone in Guadeloupe before 2003. Table B: Annual impacts and costs of liver cancer in Men exposed to chlordecone in Guadeloupe after 2003. Table C: Annual impacts and costs of liver cancer in Women exposed to chlordecone in Guadeloupe before 2003. Table D: Annual impacts and costs of liver cancer in Women exposed to chlordecone in Guadeloupe after 2003. Table E: Annual impacts and costs of prostate cancer in Men > 44 y exposed to chlordecone in Guadeloupe before 2003. Table F: Annual impacts and costs of prostate cancer in Men > 44 y exposed to chlordecone in Guadeloupe after 2003. Table G: Annual impacts and costs of renal dysfunction in Women exposed to chlordecone in Guadeloupe before 2003. Table H: Annual impacts and costs of renal dysfunction in Women exposed to chlordecone in Guadeloupe after 2003. Table I: Annual impacts and costs of cognitive development in boys born to Women exposed to chlordecone in Guadeloupe before 2003. Table J: Annual impacts and costs of cognitive development in boys born to Women exposed to chlordecone in Guadeloupe after 2003. (DOCX 122 kb) 2016-07-19 05:00:00 Chlordecone Low-dose Threshold Risk assessment Non-mutagen agent Endocrine disrupter Risk management Exposure reduction program